Goldman Sachs Group Inc Solid Biosciences Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.51 - $7.56 $123,909 - $1.84 Million	-242,960 Reduced 63.43%	140,062 $65,000
Q3 2022 Nov 10, 2022	SELL	$0.51 - $7.56 $123,909 - $1.84 Million	-242,960 Reduced 63.43%	140,062 $0
Q2 2022 May 14, 2024	BUY	$0.43 - $1.24 $164,699 - $474,947	383,022 New	383,022 $236,000
Q2 2022 Aug 15, 2022	BUY	$0.43 - $1.24 $13,163 - $37,958	30,612 Added 8.69%	383,022 $236,000
Q1 2022 May 16, 2022	SELL	$0.74 - $1.79 $97,872 - $236,745	-132,260 Reduced 27.29%	352,410 $423,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.46 $277,540 - $403,993	164,225 Added 51.25%	484,670 $848,000
Q3 2021 Nov 10, 2021	BUY	$2.38 - $3.77 $762,659 - $1.21 Million	320,445 New	320,445 $766,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $29.8M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.